Sirolimus Prolongs Survival after Living Donor Liver Transplantation for Hepatocellular Carcinoma Beyond Milan Criteria: A Prospective, Randomised, Open-Label, Multicentre Phase 2 Trial

Sirolimus (SRL) has been reported to benefit patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC). This study aimed to compare SRL with tacrolimus (TAC) in living-donor LT (LDLT) recipients beyond the Milan criteria. This study was initially designed to enrol 45 recipien...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kwang-Woong, Kim, Seong Hoon, Yoon, Kyung Chul, Lee, Jeong-Moo, Cho, Jae-Hyung, Hong, Suk Kyun, Yi, Nam-Joon, Han, Sung-Sik, Park, Sang-Jae, Suh, Kyung-Suk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600292/
https://www.ncbi.nlm.nih.gov/pubmed/33053849
http://dx.doi.org/10.3390/jcm9103264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600292/
https://www.ncbi.nlm.nih.gov/pubmed/33053849
http://dx.doi.org/10.3390/jcm9103264

Ejemplares similares